Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA

Beloor, Jagadish; Choi, Chang Seon; Nam, Hye Yeong; Park, Minsun; Kim, Sung Hwa; Jackson, Andrew; Lee, Kuen Yong; Kim, Sung Wan; Kumar, Priti; Lee, Sang Kyung

doi:10.1016/j.biomaterials.2011.11.008

Cited by 64 publications

(38 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both HSOP/siRNA micelles and HOP/siRNA micelles prepared at an N/P ratio of 30 had a neutral surface charge, which was significantly different from that of most siRNA-loaded cationic complexes reported in literature [45,46]. This neutral surface charge positively contributes to the enhanced serum stability of micelles due to reducing nonspecific interactions with anionic serum components.…”

Section: Serum Stability Of Sirna-loaded Micellesmentioning

confidence: 80%

Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer

Yin¹,

Wang²,

Yin³

et al. 2015

Biomaterials

157

View full text Add to dashboard Cite

Section: Serum Stability Of Sirna-loaded Micellesmentioning

confidence: 80%

Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer

Yin¹,

Wang²,

Yin³

et al. 2015

Biomaterials

157

View full text Add to dashboard Cite

“…Another novel theranostic nanostructure for melanoma was a NP biodegradable photoluminescent polymer-poly (lactic acid) (BPLP-PLA) loaded with anti-BRAF V600E-specific drug (PLX4032) and muramyl peptide. The new immune-cell-mediated nanoparticle offers high hopes for melanoma imaging and treatment (121)(122)(123)(124)(125)(126).…”

Section: Theranostic Nanomedicine and Melanoma Therapymentioning

confidence: 99%

Nanomedicine in Melanoma: Current Trends and Future Perspectives

El-Kenawy

Constantin

Hassan

et al. 2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:As cutaneous melanoma is a highly aggressive and drug-resistant cancer, there is intense research focusing on developing new, efficient drugs. Nanomedicine focuses on developing different groups of nanomaterials for both diagnosis and therapy, and this combination of specific diagnosis and therapy is called theranostics. Nanomaterials tailored as delivery vehicles can be nanocapsules, nanorods, nanotubes, nanoshells, and nanocages. All these structures protect the intended drug against degradation and enhance its stability. The development and characterization of polymeric nanoparticles, polymeric micelles, liposomes, nanohydrogel, dendrimers, inorganic nanoparticles, and hybrid nanocarriers are among the delivery vehicles that transport different anticancer agents. Functionalization of nanocarriers with specific molecules, such as antibodies, can generate different smart nanodrugs for application in cancer therapy and/or diagnosis. Nanotherapeutic strategies deal with several shortcomings that comprise of tumor characteristics, biological barriers, biocompatibility, and so on. As nanostructures interact with various host biomolecules, comprehensive in vitro cellular models call for evaluation of physicochemical properties, dose, and time of action of nanomaterials, while in vivo assessments would provide valuable data regarding the level of absorption, tissue/organ distribution, and metabolism. The future perspectives in nanotechnology applied to cancer overcomes the translational barrier from the laboratory to the clinical application to potentially improve conventional theranostic techniques.

show abstract

“…78 A nanoparticle was made to carry Bcl-2 siRNA (as well as Myc and VEGF) for the treatment of melanoma. 79 It was shown that this resulted in Bcl-2 reduction in both messenger ribonucleic acid (mRNA) and protein levels. This increased anticancer effects both in vitro and in vivo.…”

Section: Targeting the Mitochondrial Pathwaymentioning

confidence: 99%

Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics

Chen¹,

Shao²,

Zhang³

et al. 2013

IJN

View full text Add to dashboard Cite

Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage melanoma can be surgically removed, with a survival rate of 99%. However, metastasized melanoma is difficult to cure. The 5-year survival rates for patients with metastasized melanoma are still below 20%. Metastasized melanoma is currently treated by chemotherapy, targeted therapy, immunotherapy and radiotherapy. The outcome of most of the current therapies is far from optimistic. Although melanoma patients with a mutation in the oncogene v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) have an initially higher positive response rate to targeted therapy, the majority develop acquired drug resistance after 6 months of the therapy. To increase treatment efficacy, early diagnosis, more potent pharmacological agents, and more effective delivery systems are urgently needed. Nanotechnology has been extensively studied for melanoma treatment and diagnosis, to decrease drug resistance, increase therapeutic efficacy, and reduce side effects. In this review, we summarize the recent progress on the development of various nanoparticles for melanoma treatment and diagnosis. Several common nanoparticles, including liposome, polymersomes, dendrimers, carbon-based nanoparticles, and human albumin, have been used to deliver chemotherapeutic agents, and small interfering ribonucleic acids (siRNAs) against signaling molecules have also been tested for the treatment of melanoma. Indeed, several nanoparticle-delivered drugs have been approved by the US Food and Drug Administration and are currently in clinical trials. The application of nanoparticles could produce side effects, which will need to be reduced so that nanoparticle-delivered drugs can be safely applied in the clinical setting.

show abstract

Arginine-engrafted biodegradable polymer for the systemic delivery of therapeutic siRNA

Cited by 64 publications

References 48 publications

Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer

Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer

Nanomedicine in Melanoma: Current Trends and Future Perspectives

Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics

Contact Info

Product

Resources

About